Objective: Coronavirus Disease-2019 (COVID-19) is a pandemic outbreak in the world
and is the leading cause of Severe Acute Respiratory Syndrome (SARS).
Methods: Currently, many drugs/therapies have been tested for COVID-19, which responded sub-
-optimally to the patients. Remdesivir is an RNA polymerase inhibitor that found promising results
in ongoing clinical trials and shows a faster recovery rate in COVID-19 patients. Currently, USFDA
approves for emergent use of this drug in severe COVID-19 patients.
Results: In this review, we discussed a brief overview of biopharmaceutical and pharmacological
aspects of Remdesivir. Moreover, the ongoing regulatory status of Remdesivir by official bodies
has also been described.